|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01093 CSPC PHARMA
Nominal 
5.480 +0.540 (+10.931%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 29,009,254 | -7.761% | 31,450,109 | 30,936,904 | 27,866,870 | 24,942,204 |
| Cost of Sales | (8,710,543) | -6.070% | (9,273,423) | (8,680,490) | (6,731,776) | (6,256,882) |
| Gross Profit | 20,298,711 | -8.468% | 22,176,686 | 22,256,414 | 21,135,094 | 18,685,322 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | 32,861 | 48,065 | 37,365 | 333,055 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (89,474) | 65.093% | (54,196) | (15,395) | 22,443 | 13,532 | |
| Profit / (Loss) before Taxation | 5,578,726 | -24.503% | 7,389,372 | 7,582,261 | 6,847,096 | 6,391,023 | |
| Taxation | (1,239,901) | -5.831% | (1,316,679) | (1,350,211) | (1,158,972) | (1,162,013) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (10,790) | -94.588% | (199,368) | (140,660) | (82,939) | (69,355) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 4,328,035 | -26.310% | 5,873,325 | 6,091,390 | 5,605,185 | 5,159,655 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (188,824) | -19.301% | (233,985) | (217,637) | (175,576) | (90,588) |
| Depreciation & Amortisation | 1,339,450 | 19.862% | 1,117,490 | 1,047,939 | 865,471 | 808,807 |
| Directors' Emoluments | -- | -- | 84,048 | 73,648 | 54,944 | 49,952 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 36.870 | -25.470% | 49.470 | 51.110 | 46.890 | 43.160 |
| DPS (cts) | 23.927 | -- | 25.399 | 18.386 | 14.959 | 10.678 |
| Dividend Payout Ratio (%) | 64.896% | -- | 51.342% | 35.973% | 31.902% | 24.741% |
| Cash flow per share ($) | -- | -- | 0.352 | 0.640 | 0.388 | 0.564 |
| NBV per share ($) | 2.772 | -- | 2.789 | 2.531 | 2.175 | 1.865 |
| Remarks: | Real time quote last updated: 01/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 4,328,035 |
| %Change | -26.310% |
| EPS / (LPS) | RMB 0.369 |
| NBV Per Share (¥) | RMB 2.772 |